Ligand Pharmaceuticals will acquire Neurogen Corporation by swapping shares valued at US$11 M and granting contingent value rights (CVRs) based on certain asset sales and achieving milestones in two programmes. Ligand shareholders also gain access to an attractive partnership with Merck & Co.